Rediscovering nitroxoline : a metal-chelating agent bridging infection and cancer
(2025) In Drug Discovery Today 30(8).- Abstract
Nitroxoline, a legacy antimicrobial agent, is gaining attention for its potential repurposing in infectious diseases and oncology. Its broad-spectrum activity, including biofilm disruption and metal-chelating properties, supports diverse therapeutic applications. However, its systemic use is limited by rapid urinary excretion, short plasma half-life, and limited tissue distribution. In this review, we summarize recent advances in understanding the mechanisms of action, cross-kingdom activity, and anticancer effects of nitroxoline. Despite encouraging preclinical data, clinical translation is constrained by pharmacokinetic (PK) and regulatory challenges. As interest in repurposing established drugs grows, nitroxoline presents a... (More)
Nitroxoline, a legacy antimicrobial agent, is gaining attention for its potential repurposing in infectious diseases and oncology. Its broad-spectrum activity, including biofilm disruption and metal-chelating properties, supports diverse therapeutic applications. However, its systemic use is limited by rapid urinary excretion, short plasma half-life, and limited tissue distribution. In this review, we summarize recent advances in understanding the mechanisms of action, cross-kingdom activity, and anticancer effects of nitroxoline. Despite encouraging preclinical data, clinical translation is constrained by pharmacokinetic (PK) and regulatory challenges. As interest in repurposing established drugs grows, nitroxoline presents a compelling candidate for integration into modern therapeutic strategies across infectious and neoplastic disease domains.
(Less)
- author
- Papareddy, Praveen
LU
; Mielke, Sophie R M ; Graham, Marlowe ; Bachmann, Dennis ; Proschak, Ewgenij ; Wichelhaus, Thomas A ; Sander, Kerstin and Herwald, Heiko LU
- organization
- publishing date
- 2025-06-26
- type
- Contribution to journal
- publication status
- epub
- subject
- in
- Drug Discovery Today
- volume
- 30
- issue
- 8
- article number
- 104419
- publisher
- Elsevier
- external identifiers
-
- pmid:40581150
- ISSN
- 1878-5832
- DOI
- 10.1016/j.drudis.2025.104419
- language
- English
- LU publication?
- yes
- additional info
- Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.
- id
- 2b242d36-f176-4eab-9dd3-555d70b09940
- date added to LUP
- 2025-07-09 21:07:27
- date last changed
- 2025-07-10 09:24:13
@article{2b242d36-f176-4eab-9dd3-555d70b09940, abstract = {{<p>Nitroxoline, a legacy antimicrobial agent, is gaining attention for its potential repurposing in infectious diseases and oncology. Its broad-spectrum activity, including biofilm disruption and metal-chelating properties, supports diverse therapeutic applications. However, its systemic use is limited by rapid urinary excretion, short plasma half-life, and limited tissue distribution. In this review, we summarize recent advances in understanding the mechanisms of action, cross-kingdom activity, and anticancer effects of nitroxoline. Despite encouraging preclinical data, clinical translation is constrained by pharmacokinetic (PK) and regulatory challenges. As interest in repurposing established drugs grows, nitroxoline presents a compelling candidate for integration into modern therapeutic strategies across infectious and neoplastic disease domains.</p>}}, author = {{Papareddy, Praveen and Mielke, Sophie R M and Graham, Marlowe and Bachmann, Dennis and Proschak, Ewgenij and Wichelhaus, Thomas A and Sander, Kerstin and Herwald, Heiko}}, issn = {{1878-5832}}, language = {{eng}}, month = {{06}}, number = {{8}}, publisher = {{Elsevier}}, series = {{Drug Discovery Today}}, title = {{Rediscovering nitroxoline : a metal-chelating agent bridging infection and cancer}}, url = {{http://dx.doi.org/10.1016/j.drudis.2025.104419}}, doi = {{10.1016/j.drudis.2025.104419}}, volume = {{30}}, year = {{2025}}, }